期刊
CELLULAR AND MOLECULAR LIFE SCIENCES
卷 72, 期 7, 页码 1231-1248出版社
SPRINGER BASEL AG
DOI: 10.1007/s00018-014-1799-5
关键词
Xeno-autosialylation; Cancer glycosylation; Cancer immunoediting; Sialoglycans; Altered branching; Tumor immunosuppression
资金
- Swiss National Science Foundation [310030_135734]
- Bulgarian-Swiss Research Program (BSRP) [IZEBZO_142967]
- Swiss Cancer Research [KFS-3248-08-2013]
- CSL Behring AG, Bern, Switzerland
Aberrant glycosylation is a key feature of malignant transformation and reflects epigenetic and genetic anomalies among the multitude of molecules involved in glycan biosynthesis. Although glycan biosynthesis is not template bound, altered tumor glycosylation is not random, but associated with common glycosylation patterns. Evidence suggests that acquisition of distinct glycosylation patterns evolves from a 'microevolutionary' process conferring advantages in terms of tumor growth, tumor dissemination, and immune escape. Such glycosylation modifications also involve xeno- and hypersialylation. Xeno-autoantigens such as Neu5Gc-gangliosides provide potential targets for immunotherapy. Hypersialylation may display 'enhanced self' to escape immunosurveillance and involves several not mutually exclusive inhibitory pathways that all rely on protein-glycan interactions. A better understanding of tumor 'glycan codes' as deciphered by lectins, such as siglecs, selectins, C-type lectins and galectins, may lead to novel treatment strategies, not only in cancer, but also in autoimmune disease or transplantation.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据